These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17507321)

  • 41. Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort.
    Maggiolo F; Ripamonti D; Airoldi M; Callegaro A; Arici C; Ravasio V; Bombana E; Goglio A; Suter F
    HIV Clin Trials; 2007; 8(1):9-18. PubMed ID: 17434844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efavirenz: resistance and cross-resistance.
    Clotet B
    Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
    Kazanjian P; Tashima K; Hollander T; Kaul D
    HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
    Winters B; Van Craenenbroeck E; Van der Borght K; Lecocq P; Villacian J; Bacheler L
    J Virol Methods; 2009 Dec; 162(1-2):101-8. PubMed ID: 19654022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.
    Ross L; Liao Q; Gao H; Pham S; Tolson J; Hertogs K; Larder B; Saag MS
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1379-85. PubMed ID: 11679150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients.
    Shelton MJ; Akbari B; Hewitt RG; Adams JM; Morse GD
    J Acquir Immune Defic Syndr; 2000 May; 24(1):79-82. PubMed ID: 10877501
    [No Abstract]   [Full Text] [Related]  

  • 51. Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.
    Duarte PS
    J Nucl Med; 2021 Sep; 62(12):1833. PubMed ID: 34475238
    [No Abstract]   [Full Text] [Related]  

  • 52. Nutritional Hypersusceptibility.
    Manwaring WH
    Cal West Med; 1946 May; 64(5):287. PubMed ID: 18747258
    [No Abstract]   [Full Text] [Related]  

  • 53. Further studies upon Hypersusceptibility and Immunity.
    Rosenau MJ; Anderson JF
    J Med Res; 1907 Jul; 16(3):381-418. PubMed ID: 19971772
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical management of HIV drug resistance.
    Cortez KJ; Maldarelli F
    Viruses; 2011 Apr; 3(4):347-78. PubMed ID: 21994737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
    Demeter LM; DeGruttola V; Lustgarten S; Bettendorf D; Fischl M; Eshleman S; Spreen W; Nguyen BY; Koval CE; Eron JJ; Hammer S; Squires K
    HIV Clin Trials; 2008; 9(1):11-25. PubMed ID: 18215978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
    Haubrich RH; Jiang H; Swanstrom R; Bates M; Katzenstein D; Petch L; Fletcher CV; Fiscus SA; Gulick RM;
    HIV Clin Trials; 2007; 8(2):63-7. PubMed ID: 17507321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
    AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.